PVRIG (CD112R)
PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.
Overview
PVRIG (chromosome 7q22.1) is a cell-surface receptor for NECTIN2 (CD112) that may act as a co-inhibitory receptor suppressing T-cell receptor signals, inhibits T-cell proliferation after NECTIN2 binding and competes with CD226 for it; it is expressed at low levels on freshly isolated T and NK cells, predominantly memory and effector CD8 T cells and both CD16-positive and CD16-negative NK cells, and not on B cells, naive or helper T cells, monocytes or neutrophils (UniProt Q6DKI7). COM701 completed a phase 1/2 study with the TIGIT antibody BMS-986207 and nivolumab (NCT04570839) and is recruiting in relapsed platinum-sensitive ovarian cancer (NCT06888921).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.
- 1 · What it is
PVRIG is a brake on killer T cells and NK cells that reads CD112 on tumour cells, a cousin of the TIGIT pair. The antibody COM701 blocks it and is being tested in ovarian cancer.
- 2 · What goes wrong in cancer
An immunoglobulin-domain receptor with an ITIM-like tail; part of the CD226/TIGIT/CD96/PVRIG axis over CD155 and CD112.
- 3 · How drugs use it
No product in this corpus aims at PVRIG (CD112R) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
External identifiers
Sources: HGNC HGNC:32190 (approved symbol, name, aliases and cross-references); UniProt Q6DKI7 (protein name, function and tissue specificity)
Biology
An immunoglobulin-domain receptor with an ITIM-like tail; part of the CD226/TIGIT/CD96/PVRIG axis over CD155 and CD112.
- Memory and effector CD8 T cells and NK cells (UniProt Q6DKI7)
- Ovarian cancer trial of COM701 (NCT06888921)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"PVRIG" OR ABSTRACT:"PVRIG" OR TITLE:"CD112R" OR ABSTRACT:"CD112R" OR TITLE:"PVR related immunoglobulin domain containing" OR ABSTRACT:"PVR related immunoglobulin domain containing" OR TITLE:"C7orf15" OR ABSTRACT:"C7orf15") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PVRIG (CD112R), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCD155 (PVR)
Shares CD112 (nectin-2), TIGIT blockade, TIGIT, The cancer-immunity cycle and the tag checkpoint-map.
- TargetCD96
Shares TIGIT blockade, TIGIT, The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetKIR2DL1 (inhibitory KIR)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab, Immune checkpoint inhibitors and the tag checkpoint-map.
- TargetGITR (TNFRSF18)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab and the tag checkpoint-map.
- TargetCD27
Shares The cancer-immunity cycle, Checkpoint (two meanings), Nivolumab and the tag checkpoint-map.
- TargetLILRB2 (ILT4)
Shares The cancer-immunity cycle, Checkpoint (two meanings), Ovarian cancer and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.